Replies to post #866 on Tyme Technologies Inc. (TYME)

[mcsharkey]

Sorry about the late reply Bagel. Been a bit since on this site. Didn't have any info, AND, licking my wounds:). A Yahoo poster found this, andddddd, MAYBE a possible merger on the table????[quoteHOOKIPA promotes Christine D. Baker to Chief Operating Officer
MAY 2, 2022……..She currently serves as a non-executive Director of the Board of Tyme Technologies.
About HOOKIPA

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, that are designed to mobilize……https://www.citybiz.co/article/255215/hookipa-promotes-christine-d-baker-to-chief-operating-officer/[/quote]¯\_(?)_/¯;.
Investor Relations incommunicado about any topics submitted on RFIs. Nuthin on the HOPES Sarcoma trial. Small, real small clinic running that. Can't find much on it. On OASIS, been running long enough for some trial data to be available.

Disappointed. The merger???? I just don't know. Not looking at loading up. Did that a couple of months ago. More now accumulated then a pig can $#!*< sorry> Something I can only hope to see.
GLTUA

[mcsharkey]

Well Bagel, since you got me started. TYME Earnings Date
Well DAMN. Just been told by Investor Relations that we're in A QUIET PERIOD, so they can't answer any of my questions.

Last year ANNUAL EARNINGS report was early June. Talking heads are estimating June 9th. So it goes. I've asked for several items I ain't getting:

(1)Request for abstract and chart we presente at American Association for Cancer Research (AACR)2022, Abstract 4122,SM-88.

(2) Insight on last week's weird option awards (low strike price, long term).

And this last one we got from a poster #AnnaH over on our sister site hosted by Yahoo Finance about two days ago:

(3)HOOKIPA promotes Christine D. Baker to Chief Operating Officer
MAY 2, 2022……..She currently serves as a non-executive Director of the Board of Tyme Technologies.

INTERESTING at least to me. With earnings coming, perfect time to announce a merger?:). Cause we have to vote on that and Shareholders meetings with ballot measures be held in August.

Here's some links to Hookipa's latest SEC filings. Including some key points held on their presentation:

HOOKIPA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Outlook March 24, 2022
https://ir.hookipapharma.com/node/8126/pdf

(1)Lead oncology candidate HB-200 demonstrated high antigen-specific T cell responses and encouraging anti-tumor activity in heavily pre-treated head and neck cancer patients

(2)HOOKIPA received FDA Fast Track designation and advanced HB-200 to Phase 2 trial in combination with pembrolizumab, with data anticipated in H2 2022

(3)HOOKIPA and Gilead agreed to advance partnered HIV program, triggering $54 million commitment from Gilead

(4)Strong 2021 year-end pro forma cash position of $156.9 million when giving effect to payments received in Q1 2022 from Gilead transaction and proceeds of $75 million public follow-on offering

New data show HOOKIPA’s arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens April 13, 2022
https://ir.hookipapharma.com/node/8181/pdf

¯\_(?)_/¯